{
    "clinical_study": {
        "@rank": "168357", 
        "arm_group": {
            "arm_group_label": "Treatment (EF5)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection."
        }, 
        "brief_summary": {
            "textblock": "This pilot phase II trial studies how well EF5 works in measuring lack of tumor oxygen,\n      hypoxia, in patients with stage I-III non-small cell lung cancer. EF5 may be effective in\n      measuring the lack of oxygen in lung tumors and may allow doctors to plan better treatment."
        }, 
        "brief_title": "EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Stage IA Non-small Cell Lung Cancer", 
            "Stage IB Non-small Cell Lung Cancer", 
            "Stage IIA Non-small Cell Lung Cancer", 
            "Stage IIB Non-small Cell Lung Cancer", 
            "Stage IIIA Non-small Cell Lung Cancer", 
            "Stage IIIB Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Anoxia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Assess the frequency and degree of hypoxia as measured by EF5 binding in patients with\n      non-small cell lung cancer.\n\n      II. Correlate hypoxia as measured by EF5 binding with potential serum/plasma markers of\n      hypoxia in patients with non-small cell lung cancer.\n\n      III. Correlate hypoxia as measured by EF5 binding with tissue markers of hypoxia in patients\n      with non-small cell lung cancer.\n\n      IV. Correlate hypoxia as measured by EF5 binding with tumor angiogenesis in patients with\n      non-small cell lung cancer.\n\n      V. Correlated hypoxia as measured by EF5 binding with apoptosis in patients with non-small\n      cell lung cancer.\n\n      VI. Measure and characterize tumor perfusion in relationship to hypoxia in patients with\n      non-small cell lung cancer.\n\n      VII. Correlate tumor perfusion to microvessel density in tumor samples in patients with\n      non-small cell lung cancer.\n\n      VIII. Determine the longevity of EF5 adducts in human lung tumors.\n\n      OUTLINE:\n\n      Patients receive EF5 intravenously (IV) over 1-2.5 hours. Beginning 24-55 hours later,\n      patients undergo tumor hypoxia measurement using a polarographic needle electrode and\n      intraoperative tumor measurement before undergoing surgical biopsy or resection.\n\n      After completion of study treatment, patients are followed up for 4-6 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Known or suspected non-small cell lung cancer; patients without histologically or\n             cytologically documented non-small cell lung cancer (NSCLC) must be estimated by\n             their physician to have at least 75% probability of having NSCLC; the probability of\n             malignancy will be predicted on the basis of known probabilities of individual\n             clinical characteristics using a Bayesian model\n\n          -  Clinical or pathologic stage I to III; patients in whom pre-surgical staging has not\n             definitively establish stage IV disease are eligible\n\n          -  Tumor mass at least 1.5 cm in maximum diameter must be present on computed tomography\n             (CT) scan and must be included in the planned surgical biopsy or resection\n\n          -  Patient must be planning to undergo a surgical staging or treatment procedure\n             (including mediastinoscopy, wedge resection, lobectomy, or pneumonectomy) and have\n             the clinical and physiological status appropriate for this procedure\n\n          -  Performance status 0-2\n\n          -  Bilirubin within normal limits\n\n          -  Creatinine within normal limits or, if elevated, a creatinine clearance of at least\n             60 mL/min/m^2 (EF5 is primarily excreted via the kidney)\n\n          -  White blood cell (WBC) > 2000/mm^3\n\n          -  Platelets > 100,000/mm^3\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breast feeding; a negative serum pregnancy test is required of any woman\n             of childbearing potential prior to enrollment; pregnant women are excluded from this\n             study; breastfeeding should be discontinued if the mother is treated with EF5\n\n          -  Allergy to IV contrast dye\n\n          -  History of grade III or IV peripheral neuropathy as defined by the National Cancer\n             Institute (NCI) Common Terminology Criteria (CTC)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154399", 
            "org_study_id": "NCI-2014-01169", 
            "secondary_id": [
                "NCI-2014-01169", 
                "2310", 
                "2310", 
                "P30CA014236", 
                "R21CA091565"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (EF5)", 
                "description": "Given IV", 
                "intervention_name": "EF5", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment (EF5)", 
                "description": "Undergo surgery/thoracotomy", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (EF5)", 
                "description": "Undergo tumor hypoxia measurement", 
                "intervention_name": "tissue oxygen measurement", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (EF5)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Durham Veterans Affairs Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Michael Kelley", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency and degree of hypoxia using a polarographic needle electrode", 
                "safety_issue": "No", 
                "time_frame": "55 hours post-EF5 infusion"
            }, 
            {
                "description": "Spearman's rank correlation will be used to examine the relationship between hypoxia as measured by EF5 binding with serum markers of hypoxia (vascular endothelial growth factor [VEGF], D-Dimer, plasminogen activator inhibitor type 1 [PAI-1]).", 
                "measure": "Serum/plasma markers of hypoxia", 
                "safety_issue": "No", 
                "time_frame": "55 hours post-EF5 infusion"
            }, 
            {
                "description": "Spearman's rank correlation will be used to examine the relationship between hypoxia as measured by EF5 binding with tissue markers of hypoxia (hypoxia inducible factor 1 [HIF-1] alpha, involucrin).", 
                "measure": "Tissue markers of hypoxia", 
                "safety_issue": "No", 
                "time_frame": "55 hours post-EF5 infusion"
            }, 
            {
                "description": "Spearman's rank correlation will be used to examine the relationship between hypoxia as measured by EF5 binding with tumor perfusion.", 
                "measure": "Tumor perfusion using dynamic positron emission tomography", 
                "safety_issue": "No", 
                "time_frame": "10 days prior to surgery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}